TherapeuticsMD (TXMD) Notes Payables (2010 - 2022)

TherapeuticsMD's (TXMD) quarterly Notes Payables came in at $1.8 million in Q3 2022, down 16.59% quarter-over-quarter from $2.1 million in Q3 2012.

Analysis

TherapeuticsMD (TXMD) Notes Payables (2010 - 2022) Analysis & Trends

TherapeuticsMD (TXMD) has reported Notes Payables for 4 consecutive years, with $1.8 million the latest figure, recorded in Q3 2022.

For the quarter ending Q3 2022, Notes Payables changed N/A year-over-year to $1.8 million; the trailing twelve-month figure through Sep 2022 stood at $1.8 million (changed N/A YoY), and the FY2011 full-year result was $200000.0, down 63.2% from the prior year.
Notes Payables fell to $1.8 million in Q3 2022 per TXMD's latest filing, from $2.1 million in the prior quarter.
Across five years, Notes Payables topped out at $1.8 million in Q3 2022 and bottomed at $1.8 million in Q3 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	650.65 Bn	629.89 Bn	17.26 Bn
2	AbbVie	466.34 Bn	459.82 Bn	12.70 Bn
3	Merck	362.11 Bn	355.02 Bn	12.21 Bn
4	Novartis Ag	267.81 Bn	260.52 Bn	11.24 Bn
5	Pfizer	157.31 Bn	145.91 Bn	10.94 Bn
6	Bristol Myers Squibb	128.75 Bn	117.69 Bn	9.25 Bn
7	Sanofi	51.80 Bn	44.84 Bn	10.79 Bn
8	Revolution Medicines	40.91 Bn	40.91 Bn	-
9	BeOne Medicines	39.65 Bn	34.55 Bn	1.53 Bn
10	TherapeuticsMD	25.35 Mn	16.16 Mn	-

Historic Data

Download Data